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Since the ﬁrst vitrectomy surgery was used for treatment of vitreoretinal diseases, surgical techniques
and instrumentation have been rapidly improved in the past decades. However, there are complicated
vitreoretinal diseases that cannot be successfully treated, even with state-of-the-art surgeries. The
outcomes of some complicated cases are still poor due to different reasons and debates still remain in
some areas regarding what are the best treatments. There is still a lack of full understanding on many
complicated vitreoretinal diseases, such as the molecular basis of proliferative vitreoretinopathy (PVR),
the role of scleral buckling (SB) in the management of rhegmatogenous retinal detachment (RRD), the
optimal surgical consideration for pediatric RD, and the possibility of surgical management for various
retinal degenerations and congenital retinal anomalies. This review discusses the current understandings
of some complicated vitreoretinal diseases.
Copyright © 2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Since the ﬁrst vitrectomy surgery was used for treatment of
vitreoretinal diseases, surgical techniques and instrumentations
have been rapidly improved in the past decades. However, there are
still some complicated vitreoretinal diseases that cannot be suc-
cessfully treated, even with state-of-the-art surgeries. These chal-
lenges remain to be solved in the future. With advanced basic
research and clinical technologies, we have a better understanding
of some of the areas. This review tries to present the current un-
derstandings of some complicated vitreoretinal diseases.
2. Molecular mechanisms of proliferative vitreoretinopathy
Proliferative vitreoretinopathy (PVR) is a vision-threatening
complication after rhegmatogenous retinal detachment (RRD) or
RRD surgeries. It occurs in 5e10% of all RRD cases.1,2 Although it can
develop in untreated RD, PVR is more commonly seen after retinal
reattachment surgeries and therefore is the most common reason
of surgery failure.3 The pathogenesis of PVR includes migration ofry or commercial interest in
ogy, Central South University,
ong Road, Changsha 410015,
ciety of Taiwan. Published by Elsevcells such as retinal pigment epithelial (RPE) cells, macrophages,
and glial cells into the vitreous cavity. Proliferation and trans-
formation of these cells leads to the formation of preretinal and/or
subretinal membranes that cause retinal wrinkling and traction.4 It
is commonly believed that PVR is an analog of the wound-healing
process after retinal break formation or retinal trauma. Many fac-
tors, including vitreous, inﬂammation, and various growth factors
and cytokines, may contribute to the pathogenesis of PVR.5 Normal
vitreous contains inhibitory factors that can prevent the prolifera-
tion of ﬁbroblasts and the normal properties of vitreous also can
inhibit membrane formation.3,6,7 Alteration of the normal vitreous
properties may be a crucial step in PVR development. Vitreous from
patients with PVR has been shown to be able to stimulate RPE cells
proliferation.8
Many growth factors and cytokines may also be involved in the
pathogenesis of PVR. According to the growth factor and cytokine
hypothesis of PVR development, RPE cells and intraretinal cells are
exposed to vitreous containing growth factors and cytokines after
retinal break formation. These growth factors and cytokines may
stimulate and cause cell migration, proliferation, and extracellular
matrix formation.4 Platelet-derived growth factor (PDGF) and its
receptor (PDGFR) have been shown to be involved in the patho-
genesis of PVR. Biologically active PDGF exits asﬁve different dimers
(AA, AB, BB, CC, and DD) and its receptor exits as three dimers
(PDGFR-aa, PDGFR-bb, and PDGFR-ab).9 The level of vitreal PDGF is
higher in patients with PVR than that in patients without PVR.10e12
Lei et al11 found that PDGF-C was present in eight of nine patientsier Taiwan LLC. All rights reserved.
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PVR. PDGF is also detected in PVR membranes.13,14 Moreover, the
PDGF level in vitreous is increased in experimental animals with
PVR.10,11 Of all the isoforms, PDGF-C is the predominant isoform
detected in the vitreous of patients and animal models with PVR.11
The PDGFR is also shown to be activated in PVR membranes.15 An
in vivo experiment has shown that expression of functional PDGFR is
required for the development of PVR.16 Blocking the PDGFR can
attenuate experimental PVR.17 Studies have further shown that
activation of PDGFR-a is crucial for PVR development.15 PDGF iso-
formsdetected in thevitreousof patientswithPVRaremore likely to
activate the PDGFR-a.11 Lei et al11 analyzed different PDGF isoforms
in vitreous samples from control and PVR rabbits and from patients
with PVR. They found that the level of PDGF isoforms that activates
PDGFR-b was undetectable or very low in all of the samples tested.
By contrast, PDGF isoforms that activate PDGFR-a were present at
higher levels, especially the PDGF-C. Moreover, PDGFR-a is prefer-
entially activated in PVR membranes and it is more efﬁcient in
inducing PVR.15 Both in vivo and in vitro studies have shown that
only activation of PDGFR-a but not PDGFR-b can induce experi-
mental PVR.18,19 Fibroblasts expressing PDGFR-b have a similarly
lowpotential of inducing PVRwithﬁbroblasts not expressing PDGFR
at all, whereas ﬁbroblasts expressing PDGFR-a can potently induce
experimental PVR.18 Normal or high-level expression of PDGFR-a
can augment the PVR potential of RPE cells.19 However, blocking
PDGFs is not sufﬁcient to prevent PVR induced by PDGFR-a activa-
tion, suggesting that PDGFR-a can also be activated by non-PDGF
agents.20 Neutralizing all PDGFs in vitreous from patients or
experimental animalswith PVR could only partially inhibit PDGFR-a
activation.21 Activation of PDGFR-a by growth factors outside of the
PDGF family, namely non-PDGFs such as epidermal growth factor
(EGF), basic ﬁbroblast growth factor (bFGF), hepatocyte growth
factor (HGF), and insulinwas also involved in PVR development.20,21
As amatter of fact, the indirect activation of PDGFR-a by non-PDGFs
is a mechanism more important in inducing PVR than the direct
pathway activated by PDGFs.4 Direct activation by PDGFs leads to
assembly of PDGFR-a monomers into dimers, which are rapidly
internalized and degraded and thus the duration of the effect is
short. However, the indirect pathway of PDGFR-a activation by non-
PDGFs does not cause PDGFR-a dimers or rapid internalization and
degradation of the receptor. Therefore, the activation is more
persistent. Consistently, neutralizing non-PDGFs eliminates their
abilities to activate PDGFR-a and therefore prevent experimental
PVR.10
Vitrectomy surgeries are usually performed in patients with
severe PVR. We also tend to perform vitrectomy for those RRD
patients who have preoperative risk factors for PVR development
such as trauma, intraocular inﬂammation, giant tear, and choroidal
detachment. Complete vitrectomy should be performed in these
patients, especially at the peripheral vitreous. Complete vitrectomy
can eliminate molecules and cells in the vitreous that are associated
with PVR development, such as PDGFs and RPE cells. It can also
remove the plane where cell proliferation and membrane forma-
tion will occur. Excessive retinopexy should be avoided. An encir-
cling element may be considered to reduce the risk of recurrent RD
in cases where complete removal of the peripheral vitreous is
difﬁcult.22
3. Is scleral buckling still necessary?
Twomajor surgicalmethods used to treat RRD are scleral buckling
(SB) and pars plana vitrectomy (PPV). Although both methods have
been shown to have high success rates, there is still a large debate
about which one is the optimal treatment for uncomplicated RRD.
The decision of whichmethod to be used ismainly dependent on thesurgeon's clinical judgment, experience, and preference. There has
been a trend of treating uncomplicated RRD using primary PPV in the
past decades.23,24 In 1999, 63% of RRD cases received primary PPV in
the UK compared to only 1% in 1979e1980.23 In a large Asian tertiary
eye center, the percentage of patients who underwent primary PPV
and PPV þ SB was 39.2% in 2005 and it increased to 60.6% in 2011.24
PPV surgeries allow the surgeon to identify and treat all retinal
breaks, eliminate vitreous traction, and remove the vitreous con-
taining various factors leading to PVR. Primary PPV seems to have
better outcome in treating pseudophakic/aphakic RRD.25e28 The
Scleral Buckling versus Primary Vitrectomy in Rhegmatogenous
Retinal Detachment (SPR) study is the largest prospective random-
ized controlled trial to date to compare the efﬁcacy of SB and PPV in
treatingmediumseverity RRD. Forty-ﬁve surgeons from25 centers in
ﬁve European countries participated in the study. Patients with me-
dium severity RRD were divided into phakic and pseudophakic/
aphakic groups. Patients in each group were randomized to receive
either SB (in some cases including encircling elements) or PPVwith a
sulfur hexaﬂuoride-air mixture as endotamponade (in some cases
with additional SB). The SPR study showed that the primary
anatomical success rate was signiﬁcantly better and the mean
number of retina-affecting secondary surgeries was lower in pseu-
dophakic/aphakic RRD patients treated with PPV compared to those
treated with SB.27 In a meta-analysis, pseudophakic/aphakic RRD
treated with PPV was associated with a better ﬁnal re-attachment
rate.28 In a large sample multicenter retrospective study, pseudo-
phakic/aphakic uncomplicated RRD treated with PPV had a higher
single-surgery reattachment rate.25 The same group also recom-
mended PPV as the preferred treatment for pseudophakic/aphakic
patients with complex RRDwhen choroidal detachment, hypotony, a
large tear, or a giant tear was present.26
However, in phakic patients with uncomplicated RRD, SB
seemed to have better functional outcomes and less complications
compared to PPV while having comparable anatomical out-
comes.27e29 The SPR study showed that the SB group had signiﬁ-
cantly greater mean best-corrected visual acuity (BCVA)
improvement and less cataract progression than the PPV group.27
In a meta-analysis, SB was found to have better ﬁnal BCVA and
less postoperative cataracts compared to PPV in patients with un-
complicated phakic RRD.28 Another meta-analysis also found no
difference in the primary reattachment rate between SB and PPV in
phakic eyes with uncomplicated RRD. The authors also found better
BCVA at 6 months in phakic RRD eyes treated with SB and
contributed this to the higher rate of cataract progression in phakic
RRD eyes treated with PPV.29 A large retrospective study even
showed a signiﬁcantly lower ﬁnal failure rate in uncomplicated
RRD patients treated with SB alone.25 Moreover, SB is still the
preferred treatment in some clinical settings of RRD, e.g., patients
with localized RD and one single small retinal break, or multiple
small neighboring breaks. Most of these patients are treated with
SB.30 Another setting is young patients with uncomplicated RRD
who may otherwise need cataract surgery and lose the ability of
accommodation if treated with PPV. Incomplete vitreous detach-
ment in young patients also makes the removal of the peripheral
vitreous technically difﬁcult, which may lead to more intra- and
postoperative complications.22 In some cases, SB can also be used as
an adjunct to PPV. An encircling element to support the peripheral
retina and more importantly to release any remaining peripheral
vitreous or a PVR is useful in cases where there is residual vitreous,
severe preoperative PVR, an inferior tear, or a giant tear.22,31e33
4. Management of pediatric RRD
RRD in pediatric patients accounts for 1.7e8.0% of all RRD
patients.34e36 More boys than girls were reported, which may be
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pediatric RRD include trauma, myopia, congenital-developmental
anomalies, previous intraocular surgery, etc.34e40 Many studies
have shown myopia as one of the major risk factors of pediatric
RRD, especially in the Asian population.34,35,37 Although most RRD
can be successfully treatedwith surgery in adults, pediatric RRD is a
clinical challenge for many surgeons. Many patients present with
long disease duration and poor function. Patients may have visual
symptoms lasting for >1 month prior to presentation, which may
be due to a lack of subjective complaints in children.41,42 More
importantly, 73e92% of patients have macular involvement on
presentation, making visual recovery after surgery very
difﬁcult.35,37e40 Wang et al37 showed that the rate of macular
involvement was 92.1% in patients <10 years of age and it was 76.2%
in patients >16 years of age. Pediatric RRD also presents with a high
rate of PVR, which may be due to both long disease duration and
increased intraocular cellular activity.43 Many studies have re-
ported that >30% of the young patients had PVR (Grade C or worse)
on presentation.37e40 Younger patients seem to have a higher rate
of PVR.37,39 Soheilian et al39 showed that the rate of PVR (Grade C or
worse) was 57% in patients <10 years of age, 48% in patients be-
tween 10 years and 15 years of age and 36% in those >15 years of
age. Similarly, Wang et al37 demonstrated that PVR (Grade C or
worse) was present in 55.3% of patients <10 years of age, in 47.7% of
patients between 11 years and 15 years of age and in 41.7% of those
>15 years of age.
High PVR rate on presentation leads to low reattachment rate,
multiple surgeries, and poor visual outcomes in patients with
pediatric RRD. Complete ﬁnal retinal reattachment has been re-
ported to be achieved in only 67e85% of the cases.35,37e40 The rate
of retinal reattachment after one surgery is even lower, ranging
from 52% to 72%.37,39,40 Younger patients seem to have a lower
ﬁnal retinal reattachment rate. In a study, the ﬁnal retinal reat-
tachment rate was 61% in patients <10 years of age, 72.4% in pa-
tients between 10 years and 15 years of age and 69.7% in patients
>15 years of age.39 Another study showed anatomical success
rates of 60.5% in patients <10 years of age, 85.0% in patients be-
tween 10 years and 15 years of age and 90.1% in patients >15 years
of age.37 The etiology also seemed to affect the ﬁnal retinal reat-
tachment. Pediatric RRD caused by myopia or previous congenital
cataract surgery has the highest percentage of patients having the
retina attached at the last follow-up.39 In another study, non-
myopic RRD was one of the predictors of poor surgical
outcome.35 Many patients need multiple procedures for recurrent
RRD, cataract surgery, or silicone oil removal. The mean number of
total surgical procedures per eye ranges from 1.34 to 1.6.37e39
Gonzales et al40 reported more than one subsequent surgeries in
50% of the patients. The presence of PVR of Grade C or worse has
been shown to be associated with poor anatomical outcome.35,40
Patients with PVR (Grade C or worse) require more surgeries. It
has been shown that the average number of surgeries in eyes with
PVR Grade C or worse is signiﬁcantly higher than that for eyes
with PVR lower than Grade C.39 Visual outcomes of surgeries for
pediatric RRD are poor, due to the reasons mentioned above.
Although BCVA is improved in some patients after surgery, in
many patients BCVA remains unchanged or even worse. BCVA was
improved in only 42.8% of eyes, remained unchanged in 32.3%, and
worsened in 19.1% of eyes in a study.35 Forty-six point ﬁve percent
of eyes were considered functionally visually lost at the last
follow-up in one study39 and 31% of eyes with the ﬁnal vision of
non-light perception (NLP) in another study.38 Factors associated
with poor visual outcomes include vision of light perception only,
or undetermined vision prior to surgery, macular involvement,
presence of severe PVR (Grade C or worse), non-myopic RRD, the
need for vitrectomy, and the use of silicone oil.35,38One of the reasons of poor surgical outcomes in pediatric RRD
patients is postoperative PVR due to incomplete removal of the
vitreous. Complete posterior vitreous detachment and vitrectomy
are difﬁcult to perform in children. There have been studies using
autologous plasmin enzymes to facilitate vitreous removal.44,45
Encircling buckling or silicone oil may be helpful to patients with
incomplete vitreous removal. Aside from the poor surgical and vi-
sual outcomes of pediatric RRD, many patients also have ocular
pathologies in the fellow eye. About 37% of the fellow eye was
found to have sight-threatening ocular pathologies in a study.40 In
another study, retinal pathologies were detected in 82.2% of the
fellow eye.39 Therefore, extensive examination on presentation and
close follow-up of the fellow eye is necessary for patients with
pediatric RRD.
5. The possibilities of vitreoretinal surgeries for retinal
degeneration and retinal defect
RPE and photoreceptor damage at the macula are the major
pathologies in retinal degenerative diseases such as age-related
macular degeneration (AMD), retinitis pigmentosa (RP), and
Stargardt's macular dystrophy. A surgical approach has been
explored to reconstitute RPE and photoreceptors at the macula to
restore vision or to slow disease progression. Macular dislocation
has been used for the treatment of various macular disorders
including those caused by AMD and high myopia. In 1993,
Machemer and Steinhorst46 ﬁrst reported three cases treated by
full macular translocation (FMT). A 360 retinotomy at the pe-
ripheral retina was created after vitrectomy. Rotation of the retina
for 30e80 was then carried out and the fovea was laid on healthy
adjacent RPE. Laser photocoagulation was applied to the periph-
eral retina and intraocular tamponade was then used. Ninomiya
et al47 modiﬁed the method in 1996. Instead of creating a 360
retinotomy, they used a 180 retinal ﬂap. The extent of rotation
was also reduced to 10e20. In 1998, de Juan et al48 further
modiﬁed the technique which was called “limited macular
translocation (LMT)”. The LMT reduced the risk of postoperative
RD and PVR formation by signiﬁcantly decreasing the size of ret-
inotomy.48 They retrospectively reviewed 1-year outcomes of the
LMT in a case series of 102 eyes with neovascular AMD. In 86 eyes
that completed the 1-year follow-up, 39.5% of eyes gained two or
more Snellen lines in BCVA and 40.7% of eyes achieved BCVA of 20/
100 or better. The incidence of recurrence at 12 months was 34.6%
in eyes which had received successful macular translocation and
completed laser photocoagulation of the choroidal neo-
vascularization (CNV) complex. The recurrence was mainly sub-
foveal and led to BCVA decease.49 Toth and Freedman50 improved
the FMT with better surgical techniques and instrumentation,
which led to a decrease in surgery time and complications, and to
better visual outcomes. In a prospective study by the same group,
all of the 61 eyes with choroidal neovascularization (CNV) due to
neovascular AMD underwent successful macular translocation
and completed 12 months follow-up. Distance vision was
improved by one or more lines in 52% of patients and the median
distance visual acuity letter score was improved from 62 letters at
baseline to 69 letters at 12 months after surgery.51 Near vision and
reading speed were also improved at 12 months after surgery.51,52
The efﬁcacy of macular translocation in improving patients' vision
was conﬁrmed by a meta-analysis consisting of 32 studies using
FMT or LMT. Mean BCVA was improved from 20/133 prior to
surgery to 20/111 at ﬁnal follow-up and 31% of patients gained two
or more lines in vision. However, 27% of patients had deteriorated
by two or more lines and 16% had recurrence. The complication
rate was also high (71%) after the surgery.53 FMT has also been
used for treatment of dry AMD. Eckardt and Eckardt54 treated
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ported improved vision of two or more lines in three patients,
stable vision in four patients and reading vision gained in ﬁve
patients. However, one patient had rapid RPE atrophy develop-
ment and GA progression at the new fovea after surgery. This
complication was further conﬁrmed by other studies where rapid
foveal RPE atrophy occurred in GA patients after FMT.55,56 Several
studies have also reported the use of FMT or LMT to treat non-
AMD, such as macular degeneration caused by high myopia.57,58
In one of the studies, 38% of eyes gained more than three lines,
31% had a ﬁnal VA of 20/50 or more, and 56% had a ﬁnal VA of 20/
100 or more. However, there was no signiﬁcant difference be-
tween mean ﬁnal BCVA and mean BCVA prior to surgery.57 In a
study using LMT to treat pathological myopia, the mean BCVAwas
improved from 20/125 to 20/80 after 2 years, with 32.9% of eyes
having vision of 20/50 or more and 72% of eyes having vision of
20/100 or more. However, the reading ability of speciﬁc materials
descended from 65.8% of eyes at 6 months to 59% at 1 year and to
43% at 2 years.59
Some researchers have tried to use stem cells to preserve or
restore vision in patients with retinal degeneration. Stem cells can
be induced to differentiate into RPE cells or photoreceptors that are
used to replace the damaged cells. Stem cells can also alter the local
cellular microenvironment bymeans of releasing cytokines and cell
interactions to repair the injured tissue.60 Schwartz et al61 trans-
planted RPE cells derived from human embryonic stem cells into
the subretinal space of two patients, one with dry AMD and the
other with Stargardt's macular dystrophy. The vision of the patient
with Stargardt's macular dystrophy was improved from zero to ﬁve
letters on the early treatment diabetic retinopathy study (ETDRS)
chart 4 months after the surgery, with subjective improvement of
color vision, contrast sensitivity, and dark adaptation. Optical
coherence tomography also showed increased pigmentation at RPE
at the region of subretinal injection. The vision of the patient with
dry AMD was increased from 21 to 28 early treatment diabetic
retinopathy study (ETDRS) letters. Siqueira et al62 used intravitreal
injection of autologous bone marrow-derived mononuclear cells in
patients with RP or cone-rod dystrophy. Although no adverse event
was observed over a period of 10 months, no signiﬁcant improve-
ment in visual function was achieved either. Four of ﬁve patients
had one-line improvement in BCVA 1 week after the injection and
maintained the same until the end of the follow-up. There are
several other studies of stem cells having been used in animal
models of retinal degeneration showing promising results which
need to be conﬁrmed clinically. In fact, several clinical trials using
stem cells to treat retinal degeneration are already underway.63
Our group has published a case where a patient was treated
with retinal translocation to repair a retinal defect at the macula.
The patient was diagnosed with bilateral fungal endophthalmitis
and a large retinal defect was found at the macula of the left eye
during vitrectomy. A retinal ﬂap with vasculature was divided
from the inferior-temporal retina and translocated to the region of
retinal defect. The vision of the left eye was improved from ﬁnger
counting at 20 cm prior to surgery to 10/500 after silicone oil
removal 2 years later. Optical coherence tomography (OCT)
showed intact junction between inner segments and outer seg-
ments of the retinal photoreceptors on the translocated retina.
Normal autoﬂuorescence was shown under the translocated
retina, indicating the survival of the RPE. The patient had no
complaints of image tilting during follow-up.64 Although the
technique of retinal translocation using the adjacent retinal ﬂap is
immature and there are problems such as damage to the retinal
nerve ﬁber layer and survival of the graft, the availability and
autologous nature of the graft is a great advantage of the
technique.6. Vitreoretinal surgeries for congenital retinal anomalies
X-linked retinoschisis is a congenital retinal degeneration that
mainly affects young boys. It is estimated to occur in 1/5000e1/
25000 of the population.65,66 About 20% of the patients with X-
linked retinoschisis develop RD and one third of the patients may
develop vitreous hemorrhage (VH). Both complications can cause
severe vision loss.67e69 Observation is usually recommended for
patients with X-linked retinoschisis when there are no complica-
tions such as RD and VH.70,71 However, we have found that pa-
tients with progressive X-linked retinoschisis treated with
nonsurgical methods are more prone to develop complications
compared to those treated with early surgery. Moreover, patients
who have surgery after occurrence of complications tend to have
worse visual outcomes compared to those who have early surgery
prior to when complications occur.72 We deﬁned progress X-
linked retinoschisis as X-linked retinoschisis without complica-
tions such as RD and VH, but demonstrating progressive decrease
in vision and expansion of macular schisis or peripheral schisis
threatening the macula during more than 6 months of follow-
up.72 We divided the patients into two groups. One group was
treated with close observation and laser photocoagulation when
indicated. The other group was treated with combined vitrectomy,
internal limiting membrane peeling (ILMP), endolaser photoco-
agulation (in some cases), and gas tamponade. RD occurred in 72%
of the untreated eyes and VH occurred in 18% of the eyes in the
nonsurgical group. By contrast, only 6% of eyes developed RD and
no eye had VH in the eyes treated with early surgery. The schisis
cavity expanded in 82% of the eyes in the nonsurgical group,
whereas the schisis cavity resolved greatly in all of the eyes
treated with early surgery. The mean BCVA decreased from 20/100
at baseline to 20/400 at the ﬁnal follow-up in the nonsurgical
group; ﬁnal BCVA worsened in 91% of eyes. In the early surgery
group, the mean BCVA was improved from 20/125 at baseline to
20/55 at the ﬁnal follow-up, with ﬁnal BCVA improved in 82% of
eyes.72 Although vitrectomy is usually suggested in patients with
expanding schisis cavity and RD or VH,73,74 complete PVD is usu-
ally difﬁcult to perform in children and inner schisis wall reti-
nectomy was used in some early studies.73,74 However, this
technique results in loss of retinal ganglion cells and interneurons.
Autologous plasmin enzyme has been used to facilitate PVD.44,45
ILMP was also useful in removal of residual vitreous at the mac-
ula, while preserving the other layers of the retina.72,75
Optic disc pit is another common congenital anomaly which
equally affects men and women. About 25e75% of patients with
optic pit may develop schisis and serous RD at the macula.76
Because vision outcome of patients with untreated optic pit mac-
ulopathy is poor, treatment is usually recommended.77 Several
treatments including laser photocoagulation, intravitreal gas in-
jection, and the combination of both have been proposed.78e80
Vitrectomy is currently used in patients with optic pit maculop-
athy. The surgery is sometimes performed along with laser
photocoagulation, ILMP, and gas tamponade.81e83 Hirakata et al81
reported 11 cases of optic pit maculopathy treated with vitrec-
tomy and gas tamponade without laser photocoagulation. Com-
plete retinal reattachment was achieved in 10 eyes at the last
follow-up. Later, they treated optic pit maculopathy with vitrec-
tomy alone in eight eyes. Mean follow-upwas 26months and seven
of eight eyes had complete retinal reattachment.84
Vitrectomy has also been used in familial exudative vitreor-
etinopathy (FEVR) and persistent hyperplastic primary vitreous
(PHPV). In a study using vitrectomy to treat FEVR complicated with
RD, the ﬁnal reattachment rate was 85.7% and BCVA was improved
in 71.4% of eyes.85 Another study also showed that vitrectomy was
effective for FEVR patients with RRD, especially those without
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for PHPV would achieve useful vision.87 In a further study, lensec-
tomy and vitrectomy were effective for bilateral combined anterior
and posterior PHPV, with BCVA of 20/300 or better achieved in 71%
of eyes and 20/100 or better achieved in 57% of eyes.887. Conclusion
With the improvements in surgical techniques and advance-
ment in instrumentation, vitreoretinal surgeries have evolved
rapidly in the past decades. Surgeons now are able to treat many
vitreoretinal diseases with higher success rates than before. They
can even tackle diseases which were considered untreatable in the
past. However, there are still many challenges for vitreoretinal
surgeons. The outcomes of some complicated cases are still poor
due to many reasons. Debates still remain in some areas regarding
what are the best treatments. With further investigations into the
mechanisms of vitreoretinal diseases and with more well-
conducted clinical trials, we will be able to offer better solutions
to these challenges in the future.References
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